Skip to content
naulon

Not checkedNot checked for notices yet.

Risk of all-cause mortality or hospitalization for pneumonia associated with inhaled β2-agonists in patients with asthma, COPD or asthma-COPD overlap

Joseph Emil Amegadzie, John-Michael Gamble, Jamie Farrell and 1 more

Respiratory Research · 2022

doi:10.1186/s12931-022-02295-0 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Abstract β2-agonists provide necessary bronchodilatory action, are recommended by existing clinical practice guidelines and are widely prescribed for patients with these conditions. We examined the risk of all-cause mortality and hospitalization for pneumonia associated with long-or short-acting β2-agonists (LABA or SABA) or ICS (inhaled corticosteroids)/LABA use. In a nested case–control of 185,407 patients, we found no association between β2-agonist use and the risk of pneumonia in patients with asthma, COPD, or asthma-COPD overlap. In contrast, new SABA [HR 1.82 (95% CI 1.04–3.20)] or LABA [HR 2.77 (95% CI 1.22–6.31)] use was associated with an increased risk of all-cause mortality compared to ICS use in COPD patients.

Abstract licence: CC BY-NC-ND

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.